ワクチン受託製造の世界市場：分析 - 製品別、タイプ別、事業規模別、プロセス別、用途別、エンドユーザー別、地域別、予測（～2030年）

世界のワクチン受託製造の市場規模は、2023年に35億1,000万米ドルに達し、予測期間中にCAGR 13.1％で成長し、2030年には83億米ドルに達すると予測されています。

ワクチン受託製造は、第三者製造業者にワクチン製造を委託するものです。製薬企業は製造受託機関（CMO）と提携し、その専門知識、施設、リソースを活用して効率的かつスケーラブルなワクチン製造を行う。このアプローチにより、企業は研究開発およびマーケティングに集中できる一方、タイムリーで費用対効果の高いワクチン製造が可能になります。契約製造業者は厳格な品質基準と規制要件を遵守し、安全性と有効性を保証します。このモデルは、生産能力の柔軟性を可能にし、特にパンデミックや緊急時の世界の需要に応えるワクチンの供給を加速します。

米国小児科学会が2022年3月に発表したデータによると、米国では100万人以上が長期にわたりB型肝炎に感染しており、赤ちゃんの頃にB型肝炎に感染した人は、生涯のうちに90％の確率で肝臓がんなどの重篤な慢性疾患にかかるとされています。

ワクチン需要の増加

ワクチン需要の増加は、ワクチン受託製造市場の成長を促進する極めて重要な要因です。世界人口が予防ヘルスケア対策を優先し続ける中、効率的なワクチン製造の必要性が高まっています。ワクチン受託製造は、製薬企業がこの需要増に対応するため、迅速に生産規模を拡大できる柔軟性を提供します。さらに、専門施設に製造を委託することで、企業は研究開発に集中することができ、ワクチンの技術革新を加速させることができます。さらに、受託製造業者との提携により製造プロセスが合理化され、ワクチンをタイムリーに市場に供給することが可能になります。

品質管理の課題

品質管理の課題は主に、規制基準の厳格な遵守の必要性、複雑な製造工程、大量生産の需要に起因します。様々なバッチや施設で一貫した製品品質を確保することは、大きなハードルとなっています。さらに、製造拠点が世界各地に分散しているため、標準化と監視が複雑になっています。さらに、厳しい品質基準を維持しながら生産期限を守らなければならないという緊急性が、ミスや見落としにつながることもあります。原材料や設備のばらつきは、こうした課題をさらに悪化させます。

世界のワクチン需要

世界のワクチン受託製造市場は、世界のワクチン需要の高まりに後押しされ、大きなビジネスチャンスをもたらしています。COVID-19パンデミックの出現とワクチン接種への関心の高まりにより、生産能力の拡大が急務となっています。この市場には、柔軟性、拡張性、費用対効果といった利点があり、新興感染症や大規模な予防接種キャンペーンへの迅速な対応を可能にしています。ワクチン製造のアウトソーシングは、規制順守や資源配分など、自社製造に伴うリスクを軽減します。

知的財産の問題

多くのワクチンは特許、商標、企業秘密によって保護されており、製造方法や技術へのアクセスが制限されています。そのため、市場への参入や製造規模の拡大を目指す受託製造業者にとっては障壁となります。さらに、知的財産権をめぐる紛争は、製造業者にとって法廷闘争、遅延、コスト増につながる可能性があります。また、知的財産法の明確性や執行の欠如は、新しいワクチン製造技術に対する技術革新や投資を阻害する可能性があります。ワクチンへの公平なアクセスを確保し、競争力のある製造委託市場を育成するためには、明確なライセンシング契約と効果的な知的財産権保護メカニズムを通じてこれらの問題に対処することが極めて重要です。

COVID-19の影響：

COVID-19パンデミックは、いくつかの点でワクチン製造受託市場に大きな影響を与えました。第一に、ワクチン製造サービスに対する需要がかつてないほど急増したため、既存の製造能力に負担がかかり、製造能力の拡張と増強の必要性が生じた。第二に、ワクチン開発と流通の緊急性から、製薬企業と受託製造業者間の協力が必要となり、受託製造セクターの成長が促進されました。さらに、mRNA技術のようなワクチン製造のための先端技術への注目は、専門知識を有する受託製造業者に新たな機会を創出しました。

予測期間中、臨床分野が最大となる見込み

ワクチン受託製造市場における臨床分野は、ワクチン開発や臨床試験への投資の増加により、受託製造サービスの需要を牽引しており、堅調な伸びを示しています。さらに、感染症やパンデミックの急増がワクチン研究を加速させ、製造能力に対する需要の高まりにつながっています。さらに、バイオテクノロジーと免疫学の進歩がワクチン開発の範囲を広げ、このセグメントの成長をさらに促進しています。臨床部門は、製造のスピードと柔軟性が重要な初期段階の臨床試験に対応しており、製薬企業にとって製造委託先が不可欠なパートナーとなっています。

予測期間中にCAGRが最も高くなると予想されるのは、バイオテクノロジー企業セグメントです。

バイオテクノロジー企業が研究開発に専念するため、専門の製造受託機関（CMO）に製造を委託するケースが増えているため、バイオテクノロジー企業セグメントは力強い成長を遂げています。感染症の流行や現在進行中のCOVID-19パンデミックに牽引されたワクチン需要が、製造能力拡大の必要性を高めています。バイオテクノロジーの進歩により、より複雑なワクチンの開発が可能になり、専門的な製造技術が必要とされています。さらに、CMOが提供する柔軟性と拡張性により、バイオテクノロジー企業は変化する市場の需要や規制要件に迅速に対応することができます。

最大のシェアを占める地域

北米は高度なバイオ医薬品インフラと専門知識を誇り、ワクチン製造の外部委託を行う企業を惹きつけているため、ワクチン受託製造市場で大きな成長を遂げています。COVID-19パンデミックはワクチン製造能力に対する需要を加速させ、製薬企業は世界のニーズに迅速に対応するために製造受託サービスを求めるようになった。さらに、規制当局の支援と政府の好意的な取り組みにより、ワクチン製造パートナーシップを促進する環境が醸成されています。

CAGRが最も高い地域：

アジア太平洋は、製造インフラと熟練した労働力により大きな成長を遂げており、ワクチン製造のアウトソーシング先として魅力的な地域となっています。政府の好意的な政策や優遇措置が、多国籍製薬企業による同地域での製造施設設立を後押ししています。さらに、人口増加やヘルスケア意識の高まりを背景としたワクチン需要の増加が、市場の拡大に拍車をかけています。さらに、COVID-19パンデミックはワクチン製造能力の重要性を浮き彫りにし、政府や企業にアジア太平洋での製造能力拡大に向けた投資を促しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のワクチン受託製造市場：製品別

• 組み換えベクターワクチン
• 不活化ワクチン
• トキソイドベースワクチン
• 合成ワクチン
• 混合ワクチン
• 弱毒ワクチン
• サブユニットベースワクチン
• DNAベースワクチン
• その他の製品

第6章 世界のワクチン受託製造市場：タイプ別

• 細菌性
• ウイルス性
• その他のタイプ

第7章 世界のワクチン受託製造市場：事業規模別

• 臨床
• 商業
• 前臨床

第8章 世界のワクチン受託製造市場：プロセス別

• 下流
• 上流
• セパレーター
• 電解質
• その他のプロセス

第9章 世界のワクチン受託製造市場：用途別

• 動物用
• 人間用
• その他の用途

第10章 世界のワクチン受託製造市場：エンドユーザー別

• バイオテクノロジー企業
• 調査機関
• 製薬企業
• その他のエンドユーザー

第11章 世界のワクチン受託製造市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第12章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第13章 企業プロファイリング

• AGC Biologics
• Ajinomoto Bio-Pharma Services
• Catalent
• Charles River Laboratories International Inc.
• CJ CheilJedang Corporation
• CSL Seqirus
• Curia Global
• Emergent BioSolutions Inc.
• Fujifilm Holdings Corporation
• Gedeon Richter（Richter-Helm BioLogics）
• ICON PLC
• IDT Biologika GmbH
• KBI Biopharma
• Lonza Group AG
• Merck KGaA
• Recipharm AB
• Samsung Biologics
• WuXi Biologics

List of Tables

• Table 1 Global Vaccine Contract Manufacturing Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Vaccine Contract Manufacturing Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Vaccine Contract Manufacturing Market Outlook, By Recombinant Vector Vaccines (2021-2030) ($MN)
• Table 4 Global Vaccine Contract Manufacturing Market Outlook, By Inactivated Vaccines (2021-2030) ($MN)
• Table 5 Global Vaccine Contract Manufacturing Market Outlook, By Toxoid-based Vaccines (2021-2030) ($MN)
• Table 6 Global Vaccine Contract Manufacturing Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
• Table 7 Global Vaccine Contract Manufacturing Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
• Table 8 Global Vaccine Contract Manufacturing Market Outlook, By Attenuated Vaccines (2021-2030) ($MN)
• Table 9 Global Vaccine Contract Manufacturing Market Outlook, By Subunit-based Vaccines (2021-2030) ($MN)
• Table 10 Global Vaccine Contract Manufacturing Market Outlook, By DNA-based Vaccines (2021-2030) ($MN)
• Table 11 Global Vaccine Contract Manufacturing Market Outlook, By Other Products (2021-2030) ($MN)
• Table 12 Global Vaccine Contract Manufacturing Market Outlook, By Type (2021-2030) ($MN)
• Table 13 Global Vaccine Contract Manufacturing Market Outlook, By Bacterial (2021-2030) ($MN)
• Table 14 Global Vaccine Contract Manufacturing Market Outlook, By Viral (2021-2030) ($MN)
• Table 15 Global Vaccine Contract Manufacturing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 16 Global Vaccine Contract Manufacturing Market Outlook, By Scale of Operations (2021-2030) ($MN)
• Table 17 Global Vaccine Contract Manufacturing Market Outlook, By Clinical (2021-2030) ($MN)
• Table 18 Global Vaccine Contract Manufacturing Market Outlook, By Commercial (2021-2030) ($MN)
• Table 19 Global Vaccine Contract Manufacturing Market Outlook, By Preclinical (2021-2030) ($MN)
• Table 20 Global Vaccine Contract Manufacturing Market Outlook, By Process (2021-2030) ($MN)
• Table 21 Global Vaccine Contract Manufacturing Market Outlook, By Downstream (2021-2030) ($MN)
• Table 22 Global Vaccine Contract Manufacturing Market Outlook, By Analytical and QC Studies (2021-2030) ($MN)
• Table 23 Global Vaccine Contract Manufacturing Market Outlook, By Fill and Finish (2021-2030) ($MN)
• Table 24 Global Vaccine Contract Manufacturing Market Outlook, By Packaging (2021-2030) ($MN)
• Table 25 Global Vaccine Contract Manufacturing Market Outlook, By Other Downstream Processes (2021-2030) ($MN)
• Table 26 Global Vaccine Contract Manufacturing Market Outlook, By Upstream (2021-2030) ($MN)
• Table 27 Global Vaccine Contract Manufacturing Market Outlook, By Bacterial Expression Systems (2021-2030) ($MN)
• Table 28 Global Vaccine Contract Manufacturing Market Outlook, By Baculovirus/Insect Expression Systems (2021-2030) ($MN)
• Table 29 Global Vaccine Contract Manufacturing Market Outlook, By Mammalian Expression Systems (2021-2030) ($MN)
• Table 30 Global Vaccine Contract Manufacturing Market Outlook, By Yeast Expression Systems (2021-2030) ($MN)
• Table 31 Global Vaccine Contract Manufacturing Market Outlook, By Other Upstream Processes (2021-2030) ($MN)
• Table 32 Global Vaccine Contract Manufacturing Market Outlook, By Separator (2021-2030) ($MN)
• Table 33 Global Vaccine Contract Manufacturing Market Outlook, By Electrolyte (2021-2030) ($MN)
• Table 34 Global Vaccine Contract Manufacturing Market Outlook, By Other Processes (2021-2030) ($MN)
• Table 35 Global Vaccine Contract Manufacturing Market Outlook, By Application (2021-2030) ($MN)
• Table 36 Global Vaccine Contract Manufacturing Market Outlook, By Veterinary (2021-2030) ($MN)
• Table 37 Global Vaccine Contract Manufacturing Market Outlook, By Human Use (2021-2030) ($MN)
• Table 38 Global Vaccine Contract Manufacturing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 39 Global Vaccine Contract Manufacturing Market Outlook, By End User (2021-2030) ($MN)
• Table 40 Global Vaccine Contract Manufacturing Market Outlook, By Biotech Companies (2021-2030) ($MN)
• Table 41 Global Vaccine Contract Manufacturing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 42 Global Vaccine Contract Manufacturing Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 43 Global Vaccine Contract Manufacturing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Vaccine Contract Manufacturing Market is accounted for $3.51 billion in 2023 and is expected to reach $8.30 billion by 2030 growing at a CAGR of 13.1% during the forecast period. Vaccine contract manufacturing involves outsourcing the production of vaccines to third-party manufacturers. Pharmaceutical companies partner with contract manufacturing organizations (CMOs) to leverage their expertise, facilities, and resources for the efficient and scalable production of vaccines. This approach allows companies to focus on research, development, and marketing while ensuring timely and cost-effective manufacturing of vaccines. Contract manufacturers adhere to strict quality standards and regulatory requirements, providing assurance of safety and efficacy. This model enables flexibility in production capacity, accelerating the availability of vaccines to meet global demand, especially during pandemics or emergencies.

According to data published by the American Academy of Pediatrics in March 2022, more than 1 million people in the United States have long-term hepatitis B infections, and people who are infected with hepatitis B as a baby have a 90% chance of developing serious, chronic conditions like liver cancer in their lifetime.

Market Dynamics:

Driver:

Increasing demand for vaccines

The increasing demand for vaccines serves as a pivotal driver propelling the growth of the vaccine contract manufacturing market. As the global population continues to prioritize preventive healthcare measures, the need for efficient vaccine production escalates. Vaccine Contract Manufacturing offers pharmaceutical companies the flexibility to scale up production swiftly to meet this rising demand. Additionally, outsourcing manufacturing to specialized facilities enables companies to focus on research and development, accelerating vaccine innovation. Furthermore, partnerships with contract manufacturers streamline the production process, ensuring timely delivery of vaccines to the market.

Restraint:

Quality control challenges

Quality control challenges primarily stem from the need for strict adherence to regulatory standards, complex manufacturing processes, and the demand for high-volume production. Ensuring consistent product quality across various batches and facilities presents a significant hurdle. Additionally, the global distribution of manufacturing sites complicates standardization and oversight. Moreover, the urgency to meet production deadlines while maintaining stringent quality standards can lead to errors or oversights. Variability in raw materials and equipment further exacerbates these challenges.

Opportunity:

Global vaccine demand

The global vaccine contract manufacturing market presents a significant opportunity driven by the escalating demand for vaccines worldwide. With the advent of the COVID-19 pandemic and increased focus on vaccination, there's a pressing need for expanded production capacity. This market offers advantages such as flexibility, scalability, and cost-effectiveness, enabling swift responses to emerging infectious diseases and large-scale immunization campaigns. Outsourcing vaccine production mitigates the risks associated with in-house manufacturing, including regulatory compliance and resource allocation.

Threat:

Intellectual property issues

Many vaccines are protected by patents, trademarks, and trade secrets, limiting access to their production methods and technologies. This creates barriers for contract manufacturers seeking to enter the market or scale up production. Additionally, disputes over IP rights can lead to legal battles, delays, and increased costs for manufacturers. Lack of clarity or enforcement of IP laws can also discourage innovation and investment in new vaccine manufacturing technologies. Addressing these issues through clear licensing agreements and effective IP protection mechanisms is crucial for ensuring equitable access to vaccines and fostering a competitive contract manufacturing market.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the vaccine contract manufacturing market in several ways. Firstly, there was an unprecedented surge in demand for vaccine manufacturing services, leading to a strain on existing capacities and prompting the need for expansion and ramping up of production capabilities. Secondly, the urgency of vaccine development and distribution necessitated collaborations between pharmaceutical companies and contract manufacturers, driving growth in the contract manufacturing sector. Additionally, the focus on advanced technologies for vaccine production, such as mRNA technology, created new opportunities for contract manufacturers with specialized expertise.

The clinical segment is expected to be the largest during the forecast period

The clinical segment in the vaccine contract manufacturing market is witnessing robust growth due to increasing investments in vaccine development and clinical trials are driving demand for contract manufacturing services. Additionally, the surge in infectious diseases and pandemics has accelerated vaccine research, leading to a higher demand for manufacturing capacity. Moreover, advancements in biotechnology and immunology have widened the scope of vaccine development, further fueling growth in this segment. The clinical segment caters to early-stage trials, where speed and flexibility in manufacturing are crucial, making contract manufacturers' indispensable partners for pharmaceutical companies.

The biotech companies segment is expected to have the highest CAGR during the forecast period

The Biotech Companies segment is experiencing robust growth because biotech firms are increasingly outsourcing manufacturing to specialized contract manufacturing organizations (CMOs) to focus on research and development. The demand for vaccines, driven by infectious disease outbreaks and the ongoing COVID-19 pandemic, is driving the need for expanded manufacturing capacity. Advancements in biotechnology are enabling the development of more complex vaccines, necessitating specialized manufacturing expertise. Additionally, the flexibility and scalability offered by CMOs allow biotech companies to respond quickly to changing market demands and regulatory requirements.

Region with largest share:

North America has witnessed significant growth in the vaccine contract manufacturing market due to the region's boasting advanced biopharmaceutical infrastructure and expertise, attracting companies to outsource vaccine production. The COVID-19 pandemic has accelerated demand for vaccine manufacturing capabilities, prompting pharmaceutical firms to seek contract manufacturing services to meet global needs swiftly. Additionally, regulatory support and favourable government initiatives have fostered a conducive environment for vaccine manufacturing partnerships.

Region with highest CAGR:

The Asia-Pacific region has experienced significant growth due to the region manufacturing infrastructure coupled with a skilled workforce, making it an attractive destination for vaccine production outsourcing. Favourable government policies and incentives have encouraged multinational pharmaceutical companies to establish manufacturing facilities in the region. Moreover, the increasing demand for vaccines, driven by population growth and rising healthcare awareness, has further fueled market expansion. Furthermore, the COVID-19 pandemic has highlighted the importance of vaccine manufacturing capacity, prompting governments and companies to invest in expanding production capabilities in the Asia Pacific.

Key players in the market

Some of the key players in Vaccine Contract Manufacturing market include AGC Biologics, Ajinomoto Bio-Pharma Services, Catalent, Charles River Laboratories International Inc., CJ CheilJedang Corporation, CSL Seqirus, Curia Global, Emergent BioSolutions Inc., Fujifilm Holdings Corporation , Gedeon Richter (Richter-Helm BioLogics) , ICON PLC, IDT Biologika GmbH, KBI Biopharma, Lonza Group AG, Merck KGaA, Recipharm AB, Samsung Biologics and WuXi Biologics.

Key Developments:

In April 2024, Invenra Inc., an innovative leader in bispecific antibody technology, has announced a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.

In April 2024, Merck has launched the Aptegra CHO Genetic Stability Assay, which leverages whole-genome sequencing and bioinformatics to significantly accelerate customers' biopharmaceutical safety testing, thereby helping to accelerate customers' entry into commercial production.

Products Covered:

• Recombinant Vector Vaccines
• Inactivated Vaccines
• Toxoid-based Vaccines
• Synthetic Vaccines
• Conjugate Vaccines
• Attenuated Vaccines
• Subunit-based Vaccines
• DNA-based Vaccines
• Other Products

Types Covered:

Bacterial

Viral

Other Types

Scale of Operations Covered:

• Clinical
• Commercial
• Preclinical

Processes Covered:

• Downstream
• Upstream
• Separator
• Electrolyte
• Other Processes

Application Covered:

• Veterinary
• Human Use
• Other Applications

End Users Covered:

• Biotech Companies
• Research Institutes
• Pharmaceutical Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Vaccine Contract Manufacturing Market, By Product

• 5.1 Introduction
• 5.2 Recombinant Vector Vaccines
• 5.3 Inactivated Vaccines
• 5.4 Toxoid-based Vaccines
• 5.5 Synthetic Vaccines
• 5.6 Conjugate Vaccines
• 5.7 Attenuated Vaccines
• 5.8 Subunit-based Vaccines
• 5.9 DNA-based Vaccines
• 5.10 Other Products

6 Global Vaccine Contract Manufacturing Market, By Type

• 6.1 Introduction
• 6.2 Bacterial
• 6.3 Viral
• 6.4 Other Types

7 Global Vaccine Contract Manufacturing Market, By Scale of Operations

• 7.1 Introduction
• 7.2 Clinical
• 7.3 Commercial
• 7.4 Preclinical

8 Global Vaccine Contract Manufacturing Market, By Process

• 8.1 Introduction
• 8.2 Downstream
  • 8.2.1 Analytical and QC Studies
  • 8.2.2 Fill and Finish
  • 8.2.3 Packaging
  • 8.2.4 Other Downstream Processes
• 8.3 Upstream
  • 8.3.1 Bacterial Expression Systems
  • 8.3.2 Baculovirus/Insect Expression Systems
  • 8.3.3 Mammalian Expression Systems
  • 8.3.4 Yeast Expression Systems
  • 8.3.5 Other Upstream Processes
• 8.4 Separator
• 8.5 Electrolyte
• 8.6 Other Processes

9 Global Vaccine Contract Manufacturing Market, By Application

• 9.1 Introduction
• 9.2 Veterinary
• 9.3 Human Use
• 9.4 Other Applications

10 Global Vaccine Contract Manufacturing Market, By End User

• 10.1 Introduction
• 10.2 Biotech Companies
• 10.3 Research Institutes
• 10.4 Pharmaceutical Companies
• 10.5 Other End Users

11 Global Vaccine Contract Manufacturing Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 AGC Biologics
• 13.2 Ajinomoto Bio-Pharma Services
• 13.3 Catalent
• 13.4 Charles River Laboratories International Inc.
• 13.5 CJ CheilJedang Corporation
• 13.6 CSL Seqirus
• 13.7 Curia Global
• 13.8 Emergent BioSolutions Inc.
• 13.9 Fujifilm Holdings Corporation
• 13.10 Gedeon Richter (Richter-Helm BioLogics)
• 13.11 ICON PLC
• 13.12 IDT Biologika GmbH
• 13.13 KBI Biopharma
• 13.14 Lonza Group AG
• 13.15 Merck KGaA
• 13.16 Recipharm AB
• 13.17 Samsung Biologics
• 13.18 WuXi Biologics